Product
Supplier
Encyclopedia
Inquiry
Retatrutide( buy - large image1
Retatrutide( buy - image1
Retatrutide( buy - image2
Retatrutide( buy - image3
Retatrutide( buy - image4
Retatrutide( buy - image5
Retatrutide( buy - image6

Retatrutide(

7376 Inquiries

Unit Price:

$53/MT FOB

Get Latest Price
CAS No.:

2381089-83-2

Content:

98%

Port:

Tianjin

Packaging:

boxed

Price valid (until):

2026-11-13

Company Type:
Trader
Location:
China
Payment Terms:
TT against copy of documents,D/P,L/C,D/A,O/A,TT against B/L draft before shipment,100% TT in advance
Average Lead Time:
11 days
Qualification:
Main Products:

Peptide

  • Product Description

  • Seller Information

  • Inquiry History

  • Description


      Product Detail  


    Pls input...

    Items Specifications
    Product Name Retatrutide
    CAS NO. 2381089-83-2
    Appearance White to off-white lyophilized powder
    Purity (RP-HPLC) ≥98.0%
    Storage Conditions Store at 2–8°C protected from light; avoid repeated freeze-thaw cycles

    1.MECHANISM OF ACTION

    The mechanism of action of Retatrutide is characterized by its unique triple-agonist profile, which integrates the effects of three key metabolic hormones. By activating GLP-1 receptors, it enhances insulin secretion and suppresses glucagon release in a glucose-dependent manner while slowing gastric emptying to increase satiety; through GIP receptor agonism, it improves insulin sensitivity and may potentiate the effects on adipose tissue; and critically, by activating the glucagon receptor, it increases energy expenditure and promotes lipolysis, thereby creating a synergistic effect that not only reduces appetite but also actively burns stored fat.

    Shop Retatrutide(-Detailed Image 1

    2.PRODUCT INDICATIONS

    Retatrutide is indicated for the treatment of adults with obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) with at least one weight-related comorbidity, as well as for the management of type 2 diabetes mellitus. It is particularly suitable for patients seeking substantial weight loss beyond what is typically achievable with lifestyle modifications or first-line pharmacotherapies, including those who may be considering bariatric surgery but prefer a non-surgical alternative, and individuals requiring robust glycemic control alongside significant body weight reduction.

    Shop Retatrutide(-Detailed Image 2

    3.CLINICAL EFFICACY OF PRODUCT

    Clinical trial data, notably from the Phase 2 TRIUMPH study, demonstrate that Retatrutide achieves unprecedented levels of weight reduction, with up to 24.2% mean body weight loss at 48 weeks at the 12 mg dose, and over 30% weight loss observed in a significant proportion of participants at 72 weeks. For glycemic control, it achieved HbA1c reductions of up to 2.02%, significantly outperforming active comparators like dulaglutide. Furthermore, the product has shown efficacy in reducing liver fat content and improving cardiometabolic markers such as blood pressure and lipids, establishing it as a potent agent for comprehensive metabolic health.


    4.Certificate

    GlobalTech Co., Ltd. is committed to providing high-purity biotechnological peptide products, adhering strictly to quality standards and obtaining internationally recognized certifications.


    Our production partners all employ GMP-compliant production systems and possess standardized quality control processes covering raw material procurement, synthesis, purification, testing, packaging, and storage. Each batch of product comes with complete documentation, including a Certificate of Analysis (COA), HPLC purity report, mass spectrometry (MS) chromatograms, and third-party testing reports available upon request.


    We prioritize:

    1.A rigorous quality management system

    2.Batch traceability and stability data

    3.Professional laboratory testing and validation

    4.Compliance with international trade standards


    Our commitment to quality, transparency, and regulatory compliance ensures the provision of reliable, stable, and research-grade peptide products to our global partners.

    Shop Retatrutide(-Detailed Image 3


    5.DELIVERY & SHIPPING

    We specialize in global logistics for various cosmetic peptides. Your order will be handled with the utmost care, ensuring safe, reliable, and intact delivery.

    Professional and Secure Packaging

    Each bottle of peptide is protected with a special packaging solution to ensure stability and integrity during transportation.

    We can also customize packaging according to customer needs.

    Shipping Methods 

    Main Method: International Air Freight

    We primarily use DHL, FedEx, UPS, and TNT because of their global reliability, speed, and advanced tracking systems. Air freight ensures the fastest transit time and minimizes the impact of environmental factors on the product.

    Shop Retatrutide(-Detailed Image 4


    Global Technology Co., Ltd. is a modern and advanced enterprise specializing in the production and export of active pharmaceutical ingredients (APIs), peptides, and plant extracts. The company invests in and collaborates closely with domestic manufacturers holding GMP, DMF, and FDA certifications, as well as laboratories at renowned universities, to meet diverse customer needs ranging from gram-level to ton-level. This enables Dejurui Pharmaceutical to provide customers with more flexible and convenient access to cost-effective, high-quality products and superior services.


    We focus on the research and development and supply of high-quality chemical products, strictly adhering to international standards and quality systems. Our products are stable in performance and reliable in purity, widely used in industrial manufacturing, scientific research, and the fine chemical industry. We provide solid support at every stage with a professional and responsible attitude.


    HotTags:Retatrutide, TripleAgonist, ObesityTreatment, Type2Diabetes, WeightLossJourney, GLP1Agonist, MetabolicHealth, EliLilly, ClinicalTrials, NewDrug, FatLoss, IncretinTherapy Supplier, Manufacturer, Bulk order,  Pharmaceutical.





    Does  R etatrutide  A ctually  B urn  F at?


    Retatrutide is an experimental medication being studied for obesity and metabolic disease, and it has drawn attention for its impressive weight-loss effects in clinical trials. However, it does not “burn fat” in the simple sense of directly destroying fat tissue. Instead, it works through complex hormonal pathways that lead the body to reduce fat stores over time.

    Retatrutide activates three key hormone receptors: GLP-1, GIP, and glucagon. These hormones regulate appetite, blood sugar, and energy balance. By stimulating GLP-1 and GIP pathways—similar to drugs like Tirzepatide—it significantly reduces hunger and food intake, helping people consume fewer calories. At the same time, its glucagon receptor activity may slightly increase energy expenditure, meaning the body uses more calories at rest. This combination creates a sustained calorie deficit, which leads to fat loss.

    Clinical studies have shown that people taking retatrutide can lose a substantial percentage of their body weight, much of which comes from fat mass rather than muscle. This distinguishes it from crash dieting, where muscle loss can be significant. The drug also improves metabolic markers such as insulin sensitivity and lipid levels, suggesting that the fat loss is accompanied by broader health benefits.

    That said, retatrutide is still under investigation and has not yet been widely approved for general use. Its long-term safety, optimal dosing, and full mechanism of action are still being studied. Side effects reported so far are similar to other drugs in this class, including nausea, vomiting, and gastrointestinal discomfort.

    In summary, retatrutide does not literally “burn fat” like a furnace, but it creates biological conditions—reduced appetite and possibly increased energy use—that lead the body to gradually reduce stored fat.



    Retatrutide  B enefits


    Retatrutide is an investigational therapy that has shown a range of promising benefits in early clinical studies, particularly for people with obesity and metabolic disorders. Its unique mechanism targets three hormone receptors—GLP-1, GIP, and glucagon—allowing it to influence multiple aspects of energy balance and metabolism at the same time.

    One of the most notable benefits of retatrutide is substantial weight loss. In clinical trials, participants have experienced significant reductions in body weight, often exceeding what has been observed with earlier medications such as Tirzepatide. This weight loss is largely driven by decreased appetite, increased feelings of fullness, and reduced overall calorie intake. In addition, the drug may modestly increase energy expenditure through its glucagon-related effects, further supporting fat reduction.

    Beyond weight management, retatrutide has demonstrated improvements in metabolic health. It can help lower blood glucose levels, making it potentially useful for individuals with Type 2 Diabetes or insulin resistance. Patients in studies have also shown better insulin sensitivity and improved lipid profiles, including reductions in triglycerides and LDL cholesterol.

    Another important benefit is its potential impact on cardiovascular risk factors. By promoting weight loss and improving metabolic markers, retatrutide may indirectly reduce the risk of heart disease, although long-term outcome data are still being collected. Some research also suggests it could help reduce liver fat, which may be beneficial for conditions like nonalcoholic fatty liver disease.

    Despite these advantages, retatrutide remains under investigation and is not yet widely approved for routine clinical use. Its long-term safety, tolerability, and optimal use still require further study. Overall, it represents a promising advancement in the treatment of obesity and related metabolic conditions, offering a more comprehensive and multifaceted approach than earlier therapies.



    Retatrutide  H ow to  G et


    Retatrutide is still an investigational drug, so you generally cannot obtain it through standard prescriptions or pharmacies at this time. Unlike approved medications such as Tirzepatide, retatrutide has not yet received full regulatory approval from agencies like the U.S. Food and Drug Administration. This means it is not legally available for routine clinical use.

    The primary way to access retatrutide right now is through participation in clinical trials. These studies are conducted to evaluate the drug’s safety, effectiveness, and appropriate dosing. Individuals who meet specific eligibility criteria—such as having obesity or Type 2 Diabetes—may be able to enroll. Clinical trials are typically run by research hospitals, universities, or pharmaceutical companies, and participants are closely monitored by medical professionals throughout the study.

    To find trials, people often search databases such as ClinicalTrials.gov or consult with their healthcare provider, who may know of local research programs. However, enrollment is not guaranteed, as each trial has strict inclusion and exclusion criteria, and available spots may be limited.

    It is important to be cautious about online sources claiming to sell retatrutide. Because the drug is not approved, any products marketed directly to consumers are likely unregulated and may be unsafe, counterfeit, or ineffective. Purchasing such substances can carry significant health risks.

    In the future, if ongoing trials continue to show positive results, retatrutide may become more widely available through prescription after regulatory approval. Until then, the safest and most legitimate path to access is through properly conducted clinical research under medical supervision.

    If you are interested in our products, please contact us proactively!

    We will provide you with the highest quality service!

    NAME: Zoe
    WHATSAPP:+852 9864 1364
    EMAIL:2096860470@qq.com

    ECHEMI Editorial Reference
    Retatrutide is a novel triple agonist peptide of the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide inhibits human GCGR, GIPR and GLP-1R with EC50 values of 5.79, 0.0643 and 0.775 nM, respectively and mouse GCGR, GIPR, and GLP-1R with EC50 values of 2.32, 0.191 and 0.794 nM, respectively. It is an important tool for obesity research.Retatrutide potently activates the GLP-1R signaling pathway to stimulate glucose-dependent insulin secretion through activity at the GIP receptor (GIPR) or the GLP-1R.Retatrutide is a synthetic peptide with glucose-lowering effects. It is an antidiabetic agent against type 2 diabetes (T2D), stimulating insulin and suppressing glucagon secretion in a glucose-dependent manner.Retatrutide was also shown to delay gastric emptying, lower fasting and postprandial glucose concentration, decrease food intake and reduce body weight in patients with type 2 diabetes.
    Retatrutide (LY-3437943) was discovered by the American pharmaceutical company Eli Lilly and Company. It is a triple glucagon hormone receptor agonist (GLP-1, GIP, and GCGR receptors) for obesity. The 2024 Lasker~DeBakey Clinical Medical Research Award has been given to Joel Habener and Svetlana Mojsov for their discovery of a new hormone GLP-1(7-37) and to Lotte Knudsen for her role in developing sustained acting versions of this hormone as a treatment for obesity.

    Basic Info
    Product Name:

    Retatrutide

    Other Name:

    Retatrutide;GIPR/GLP-1R;LY3437943Retatrutide;Retalutide;Retatrutide (sodium salt);Retatrutide RT5;retatrutide 5mg;Retatratide

    CAS No.:

    2381089-83-2

    InChIKeys:

    MLOLQJNKXBNWFW-SAGGEDDASA-N

    Molecular Weight:

    0

    EC Number:

    200-001-8

    Color/Form:

    White lyophilized

    Categories:

    Polypeptide

    Characteristics
    Water Solubility:

    Soluble in water (5mg/ml).

    Storage Conditions:

    -20°C

    Critical Temperature & Pressure:

    -20°C

    Research
    Class:

    Triple agonist — GCGR, GIPR, GLP-1R

    Status:

    Investigational (Phase 3)

    Mechanism:

    Simultaneously activates glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Engineered from the native GIP backbone with amino acid substitutions to confer GCGR and GLP-1R activity.

    EC50 (Human GCGR):

    5.79 nM

    EC50 (Mouse GIPR):

    0.191 nM

    EC50 (Mouse GLP1R):

    0.794 nM

    EC50 (Mouse GCGR):

    2.32 nM

    EC50 (Human GLP1R):

    0.775 nM

    EC50 (Human GIPR):

    0.0643 nM

    Source:

    Jastreboff AM, et al. N Engl J Med. 2023;389(6):514-526.DOI

    Clinical Development:

    NCT04881760; NCT05882045; NCT06354660

    References
    ChEMBL:

    CHEMBL5095485

    DrugBank:

    DB18993

    KEGG DRUG:

    D12430

    PubChem:

    PubChem

    Disclaimer:

    Retatrutide is an investigational compound not yet approved by FDA or EMA. This listing is for industrial and laboratory research use only. Product information on ECHEMI is provided for sourcing and specification reference. It is not medical advice, a clinical recommendation, or an approved therapy description. Always verify regulatory status, purity, and intended use with the supplier and applicable authorities before purchase or use.

  • Seller Information
    Business Type:

    Trader

    Main Products:

    Peptide

    Location:

    Room 1501, Building 1, Changnan Mansion, Country Garden, on the west side of Taoyang North Road

    Payment Terms:

    TT against copy of documents,D/P,L/C,D/A,O/A,TT against B/L draft before shipment,100% TT in advance

    Average lead Time:

    11 days

    Year of Establishment:

    2025

  • Inquiry History
    7376 Inquiries
    Country Product Purchase Quantity Date Posted
    United States

    Retatrutide 2381089-83-2

    3 MT Mar 28, 2026
    United Kingdom

    Retatrutide - 2381089-83-2

    1 G Feb 10, 2026
    United States

    Retatrutide CAS 2381089-83-2 10mg vial

    20 MT Mar 7, 2026
    United States

    Factory Retatrutide API 99% Purity CAS 2381089-83-2

    5 KG Nov 10, 2025
    United Kingdom

    Peptide powder Retatrutide 99% pure for Body building cas 2381089-83-2 Weight Loss Peptide with COA

    1 MT Mar 22, 2026
    United States

    2381089-83-2

    100 G Jul 14, 2026
    United States

    2381089-83-2

    100 G Feb 24, 2026
    United States

    2381089-83-2

    100 MT Dec 9, 2023
    United States

    Retatrutide 2381089-83-2

    200 MG May 16, 2026
    United Kingdom

    2381089-83-2 retatrutide

    300 MG Feb 13, 2026
    United States

    Retatrutide 2381089-83-2 wholesale

    500 MT Nov 3, 2023
    Austria

    Retatrutide CAS 2381089-83-2 10mg vial

    20 PCS Feb 10, 2026
    United States

    Retatrutide CAS 2381089-83-2 99%

    10 PCS Feb 21, 2026
    Poland

    CAS 2381089-83-2 (Custom Peptide)

    40 MT Apr 10, 2026
    Austria

    Peptide Retatruide CAS 2381089-83-2

    100 MT Apr 4, 2026
    United States

    GLP-1 / GIP Retatrutide cas 2381089-83-2

    1 MT Oct 16, 2024
    United States

    Retatrutide 99% High Quality CAS 2381089-83-2

    1 G Jan 23, 2026
    Palestine

    Factory 99% Purity Retatrutide Peptide CAS 2381089-83-2 Door-To-Door Service

    10 MG Mar 16, 2026
    United States

    Factory 99% Purity Retatrutide Peptide CAS 2381089-83-2 Door-To-Door Service

    20 MG Feb 4, 2026
    Singapore

    Factory 99% Purity Retatrutide Peptide CAS 2381089-83-2 Door-To-Door Service

    100 MG Jun 28, 2025
    Post an enquiry for this product
pic ×

Scan the QR Code to Share

All products displayed on this website are only for non-medical purposes such as industrial applications or scientific research, and cannot be used for clinical diagnosis or treatment of humans or animals. They are not medicinal or edible.

According to relevant laws and regulations and the regulations of this website, units or individuals who purchase hazardous materials should obtain valid qualifications and qualification conditions.

The information shown above is provided by the enterprise itself, and the authenticity, accuracy and legitimacy of the content are the responsibility of the publishing company. ECHEMI does not bear any guarantee responsibility for this. Please be aware that risks in internet transactions objectively exist.

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.